Cannabinoids - Signal transduction and mode of action;Cannabinoide - Signaltransduktion und wirkung

Schmerz

Volumn 19, Issue 6, 2005, Pages 528-534

  Rukwied, R ^a   Gauter, B ^a   Schley, M ^a   Konrad, C ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Agonist; Antagonist; Cannabinoid receptor; Cannabinoids; Receptor interaction

Indexed keywords

ADENYLATE CYCLASE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR AGONIST; NEUROTRANSMITTER;

CANCER INHIBITION; CHRONIC PAIN; CLINICAL RESEARCH; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SENSITIZATION; ENZYME INHIBITION; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; NAUSEA AND VOMITING; NEUROTRANSMITTER RELEASE; NONHUMAN; PAIN ASSESSMENT; PAIN THRESHOLD; PRURITUS; REVIEW; SIGNAL TRANSDUCTION; WEIGHT REDUCTION;

ANIMALS; CANNABINOIDS; DISEASE MODELS, ANIMAL; HUMANS; PAIN; PAIN MEASUREMENT; PRESYNAPTIC TERMINALS; RECEPTORS, CANNABINOID; SIGNAL TRANSDUCTION; SYNAPSES;

EID: 27944453165     PISSN: 0932433X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00482-004-0349-8     Document Type: Review

References (30)

1. Atkins CM, Selcher JC, Petraitis JJ, Trzaskos JM, Sweatt JD (1998) The MAPK cascade is required for mammalian associative learning. Nat Neurosci 1:602-609
2. Beal JE, Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B, Morales JO, Murphy R, Powderly W, Plasse TF, Mosdell KW, Shepard KV (1997) Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 14:7-14
3. Berdyshev EV (2000) Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids 108:169-190
4. Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ (2003) Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain 106:169-172
5. Cichewicz DL, McCarthy EA (2003) Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther 304:1010-1015
6. Croxford JL (2003) Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 17:179-202
7. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372:686-691
8. Di Marzo V, Melck D, De Petrocellis L, Bisogno T (2000) Cannabimimetic fatty acid derivatives in cancer and inflammation. Prostagland Other Lipid Mediat 61:43-61
9. Elsner F, Radbruch L, Sabatowski R (2001) Tetrahydrocannabinol for treatment of chronic pain. Schmerz 15:200-204
10. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54-61
11. Guhring H, Schuster J, Hamza M, Ates M, Kotalla CE, Brune K (2001) HU-210 shows higher efficacy and potency than morphine after intrathecal administration in the mouse formalin test. Eur J Pharmacol 429:127-134
12. Guzman M, Sanchez C, Galve-Roperh I (2001) Control of the cell survival/death decision by cannabinoids. J Mol Med 78:613-625
13. Helyes Z, Nemeth J, Than M, Bolcskei K, Pinter E, Szolcsanyi J (2003) Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat. Life Sci 73:2345-2353
14. Hsieh C, Brown S, Derleth C, Mackie K (1999) Internalization and recycling of the CB1 cannabinoid receptor. J Neurochem 73:493-501
15. Iversen L (2003) Cannabis and the brain. Brain 126:1252-1270
16. Maccarrone M, Bari M, Principe DD, Finazzi-Agro A (2003) Activation of human platelets by 2-arachidonoylglycerol is enhanced by serotonin. Thromb Haemost 89:340-347
17. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgänsberger W, Di Marzo V, Lutz B (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530-534
18. Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF, Ferri GL, Sibaev A, Storr M, Lutz B (2004) The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113:1202-1209
19. Melck D, Rueda D, Galve-Roperh I, De Petrocellis L, Guzman M, Di Marzo V (1999) Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett 463:235-240
20. Melis M, Pistis M, Perra S, Muntoni AL, Pillolla G, Gessa GL (2004) Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci 24:53-62
21. Neff GW, O'Brien CB, Reddy KR, Bergasa NV, Regev A, Molina E, Amaro R, Rodriguez MJ, Chase V, Jeffers L, Schiff E (2002) Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol 97:2117-2119
22. O'Shaughnessy WB (1840) On the preparations of indian hemp, or gunja (cannabis indica): their effects on the animal system in health and their utility in the treatment of tetanus and other convulsive diseases. Trans Med Phys Soc Bengal:421-461
23. Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129-180
24. Rice AS, Farquhar-Smith WP, Nagy I (2002) Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostagland Leukot Essent Fatty Acids 66:243-256
25. Rukwied R, Watkinson A, McGlone F, Dvorak M (2003) Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 102:283-288
26. Schwenkreis P, Tegenthoff M (2003) Therapeutic use of cannabinoids in neurology. Schmerz 17:367-373
27. Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ (2003) Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain 102:211-216
28. Yesilyurt O, Dogrul A, Gul H, Seyrek M, Kusmez O, Ozkan Y, Yildiz O (2003) Topical cannabinoid enhances topical morphine antinociception. Pain 105:303-308
29. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomized placebo-controlled trial. Lancet 362:1517-1526
30. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D, Hogestatt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452-457